肝癌肝移植转化治疗策略进展

卢倩; 童翾; 汤睿

doi:10.3969/j.issn.1001-5256.2021.02.003

肝癌肝移植转化治疗策略进展

DOI: 10.3969/j.issn.1001-5256.2021.02.003

清华大学附属北京清华长庚医院肝胆胰中心，清华大学临床医学院，清华大学精准医学研究院，北京 102218

基金项目:

国家科技重大专项 (2017ZX100203205);

国家自然科学基金 (81930119)

作者贡献声明：童翾负责课题设计，资料分析，撰写论文；汤睿参与收集数据，修改论文；卢倩负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

作者简介:
卢倩(1976—)，女，副主任医师，博士，主要从事肝胆胰外科和肝移植方面研究

通信作者:
卢倩，luqianbtch@163.com

中图分类号: R735.7;R617
计量
- 文章访问数: 888
- HTML全文浏览量: 283
- PDF下载量: 91
- 被引次数: 0
出版历程
- 收稿日期: 2021-01-05
- 录用日期: 2021-01-08
- 出版日期: 2021-02-20

Advances in conversion therapy strategies for liver transplantation for liver cancer

Hepatobiliary and Pancreatic Center, Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital & School of Clinical Medicine, Tsinghua University & Institute of Precision Medicine, Tsinghua University, Beijing 102218, China

摘要

摘要: 肝移植能够在彻底去除肿瘤的同时完整移除病肝，对于合并肝硬化的肝癌患者是最佳选择。近年来，随着肝癌综合治疗研究的进展，转化治疗理念被引入肝癌外科治疗领域以及肝移植领域，成功的转化治疗有望将超出标准肝癌患者转变为符合标准而接受肝移植手术，从而极大改善其预后。就肝癌肝移植转化治疗的进展进行简要介绍。
- 肝肿瘤 /
- 肝移植 /
- 治疗学
Abstract: Liver transplantation can completely remove the tumor and the diseased liver at the same time and is the best choice for patients with liver cancer and liver cirrhosis. With the advances in multimodality therapy for liver cancer in recent years, the concept of conversion therapy has been introduced into the fields of surgical treatment of liver cancer and liver transplantation, and successful conversion therapy is expected to help ineligible liver cancer patients to meet the criteria for liver transplantation and thus improve their prognosis. This article briefly introduces the advances in conversion therapy for liver transplantation for liver cancer.
- Liver Neoplasms /
- Liver Transplantation /
- Therapeutics

HTML全文

参考文献(31)

[1]	ZHENG RS, SUN KX, ZHANG SW, et al. Report of cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(1): 19-28. (in Chinese) 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
[2]	TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262
[3]	Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.02.007 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007
[4]	MAZZAFERRO V, REGALIA E, DOCI R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699. DOI: 10.1056/NEJM199603143341104
[5]	YAO FY, FERRELL L, BASS NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival[J]. Hepatology, 2001, 33(6): 1394-1403. DOI: 10.1053/jhep.2001.24563
[6]	ZHENG SS, XU X, WU J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences[J]. Transplantation, 2008, 85(12): 1726-1732. DOI: 10.1097/TP. 0b013e31816b67e4
[7]	YAO FY, MEHTA N, FLEMMING J, et al. Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria[J]. Hepatology, 2015, 61(6): 1968-1977. DOI: 10.1002/hep.27752
[8]	Organ Transplantation Branch, Chinese Medical Doctor Association; Chinese Society of Organ Transplantation, Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (2018)[J]. J Clin Hepatol, 2019, 35(2): 275-280. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.02.008 中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008
[9]	BRUIX J, SHERMAN M, LLOVET JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver[J]. J Hepatol, 2001, 35(3): 421-430. DOI: 10.1016/S0168-8278(01)00130-1
[10]	European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908-943. DOI: 10.1016/j.jhep.2011.12.001
[11]	CLAVIEN PA, LESURTEL M, BOSSUYT PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report[J]. Lancet Oncol, 2012, 13(1): e11-e22. DOI: 10.1016/S1470-2045(11)70175-9
[12]	WANG H, CHEN G, GAO HJ, et al. The value of DEB-TACE as down-stage therapy for hepatocellular carcinoma before liver transplantation[J]. Chin J Gen Surg, 2019, 34(5): 410-412. (in Chinese) DOI: 10.3760/cma.j.issn.1007-631X.2019.05.009 王浩, 陈光, 高海军, 等. 载药微球介入栓塞治疗在肝癌肝移植术前降期治疗中的应用[J]. 中华普通外科杂志, 2019, 34(5): 410-412. DOI: 10.3760/cma.j.issn.1007-631X.2019.05.009
[13]	BOUCHARD-FORTIER A, LAPOINTE R, PERREAULT P, et al. Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: A retrospective study[J]. Int J Hepatol, 2011, 2011: 974514.
[14]	CHOI SH, SEONG J. Strategic application of radiotherapy for hepatocellular carcinoma[J]. Clin Mol Hepatol, 2018, 24(2): 114-134. DOI: 10.3350/cmh.2017.0073
[15]	CHONG JU, CHOI GH, HAN DH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2018, 25(11): 3308-3315. DOI: 10.1245/s10434-018-6653-9
[16]	ASSALINO M, TERRAZ S, GRAT M, et al. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study[J]. Transpl Int, 2020, 33(5): 567-575. DOI: 10.1111/tri.13586
[17]	Chinese Society of Liver Cancer, Chinese Medical Doctor Association. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018)[J]. J Clin Hepatol, 2019, 35(4): 737-743. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.04.008 中国医师协会肝癌专业委员会. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版)[J]. 临床肝胆病杂志, 2019, 35(4): 737-743. DOI: 10.3969/j.issn.1001-5256.2019.04.008
[18]	PRACHT M, EDELINE J, LENOIR L, et al. Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: Preliminary results[J]. Int J Hepatol, 2013, 2013: 827649.
[19]	CHENG AL, KANG YK, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34. DOI: 10.1016/S1470-2045(08)70285-7
[20]	IKEDA M, OKUSAKA T, MITSUNAGA S, et al. Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res, 2016, 22(6): 1385-1394. DOI: 10.1158/1078-0432.CCR-15-1354
[21]	EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2
[22]	ZHU AX, FINN RS, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952. DOI: 10.1016/S1470-2045(18)30351-6
[23]	IRTAN S, CHOPIN-LALY X, RONOT M, et al. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection[J]. Liver Int, 2011, 31(5): 740-743. DOI: 10.1111/j.1478-3231.2010.02441.x
[24]	VAGEFI PA, HIROSE R. Downstaging of hepatocellular carcinoma prior to liver transplant: Is there a role for adjuvant sorafenib in locoregional therapy?[J]. J Gastrointest Cancer, 2010, 41(4): 217-220. DOI: 10.1007/s12029-010-9163-y
[25]	JENG KS, HUANG CC, LIN CC, et al. Liver transplantation after downstagings of ruptured advanced hepatocellular carcinoma in cirrhotic liver: Is it advisable? A case report[J]. Transplant Proc, 2019, 51(5): 1468-1471. DOI: 10.1016/j.transproceed.2019.01.125
[26]	HU B, YANG XB, SANG XT. Liver graft rejection following immune checkpoint inhibitors treatment: A review[J]. Med Oncol, 2019, 36(11): 94. DOI: 10.1007/s12032-019-1316-7
[27]	NORDNESS MF, HAMEL S, GODFREY CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2020, 20(3): 879-883. DOI: 10.1111/ajt.15617
[28]	KITTAI AS, OLDHAM H, CETNAR J, et al. Immune checkpoint inhibitors in organ transplant patients[J]. J Immunother, 2017, 40(7): 277-281. DOI: 10.1097/CJI.0000000000000180
[29]	COHEN GS, BLACK M. Multidisciplinary management of hepatocellular carcinoma: A model for therapy[J]. J Multidiscip Healthc, 2013, 6: 189-195.
[30]	SIDDIQUE O, YOO ER, PERUMPAIL RB, et al. The importance of a multidisciplinary approach to hepatocellular carcinoma[J]. J Multidiscip Healthc, 2017, 10: 95-100. DOI: 10.2147/JMDH.S128629
[31]	TRIOLO M, SANGIOVANNI A, LA MURA V, et al. Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations[J]. Dig Liver Dis, 2016, 48(Suppl 1): e26.